Objective-The objective of this study is to investigate the role and underlying mechanism of Olfactomedin 2 (Olfm2) in smooth muscle cell (SMC) phenotypic modulation and vascular remodeling. Approach and Results-Platelet-derived growth factor-BB induces Olfm2 expression in primary SMCs while modulating SMC phenotype as shown by the downregulation of SMC marker proteins. Knockdown of Olfm2 blocks platelet-derived growth factor-BB-induced SMC phenotypic modulation, proliferation, and migration. Conversely, Olfm2 overexpression inhibits SMC marker expression. Mechanistically, Olfm2 promotes the interaction of serum response factor with the runt-related transcription factor 2 that is induced by platelet-derived growth factor-BB, leading to a decreased interaction between serum response factor and myocardin, causing a repression of SMC marker gene transcription and consequently SMC phenotypic modulation. Animal studies show that Olfm2 is upregulated in balloon-injured rat carotid arteries. Knockdown of Olfm2 effectively inhibits balloon injury-induced neointima formation. Importantly, knockout of Olfm2 in mice profoundly suppresses wire injury-induced neointimal hyperplasia while restoring SMC contractile protein expression, suggesting that Olfm2 plays a critical role in SMC phenotypic modulation in vivo. Conclusions-Olfm2 is a novel factor mediating SMC phenotypic modulation. Thus, Olfm2 may be a potential target for treating injury-induced proliferative vascular diseases. Visual Overview-An online visual overview is available for this article.
V ascular smooth muscle cells (SMCs) do not terminally differentiate and can undergo transition between a quiescent contractile phenotype and a proliferative synthetic phenotype in response to pathological stimuli, such as vascular injury. 1 This phenotypic plasticity of SMCs is essential for vascular development and remodeling. Fully differentiated SMCs express high levels of smooth muscle contractile proteins such as smooth muscle myosin heavy chain (MYH11 [myosin heavy chain 11]), SM22α (TAGLN [transgelin]), and α-smooth muscle actin (ACTA2 [actin alpha 2]) that are required to fulfill their principal contractile function. Proliferating SMCs, in contrast, express reduced levels of contractile proteins. Consequently, changes of SMC contractile gene expression are often used to mark SMC phenotype alteration. 1 Platelet-derived growth factor-BB (PDGF-BB) is one of the key modulators for SMC phenotypes. 1 In cultured SMCs, PDGF-BB represses the expression of SMC markers while increasing SMC proliferation and migration rates. [2] [3] [4] In vivo, the expression of PDGF-BB and PDGF-β receptor is increased at the site of vascular lesions, and inhibition of their signaling has been reported to reduce neointimal thickening. [5] [6] [7] [8] [9] The PDGF-BB-induced repression of SMC genes at the transcriptional level is serum response factor (SRF)-dependent manner. [10] [11] [12] [13] SRF, a widely expressed MADS (MCM1 [minichromosome maintenance 1], Agamous, Deficiens, and SRF) box transcription factor, binds as a homodimer to a DNA consensus sequence known as a CArG box (CC [A/T] 6 GG), which is found in the 5′ promoter and intronic regions of SMC-specific genes.
14 SRF binding to CArG box is a critical step for the activation of SMC-specific genes in vascular SMC differentiation. High SRF expression facilitates SRF-CArG binding. Transforming growth factor-β (TGF-β), a potent stimulator of SMC differentiation, has been shown to induce SRF expression via undefined mechanisms. 15, 16 Moreover, SRF can interact with other transcription factors or cofactors to promote SMC differentiation. Among them, myocardin (Myocd) is the most powerful SRF cofactor that is expressed in smooth and cardiac muscle lineages throughout embryonic development and adulthood. 17 Myocd stimulates SRF-dependent transcription by interacting with the MADS domain of SRF. 18, 19 Myocd is upregulated at the transcriptional level in the late stage of TGF-β-induced SMC differentiation from mesenchymal stem cells. 20, 21 In addition to their expression level being regulated in SMC differentiation, both SRF and Myocd may undergo post-translational modification such as phosphorylation, which affects SRF/Myocd activity in SMC differentiation. [22] [23] [24] Recent studies have revealed that runt-related transcription factor 2 (Runx2), a key osteogenic transcription factor, serves as a corepressor independent of its DNA binding by interacting with SRF and disrupting the formation of SRF/Myocd complex, which contributes to the phenotypic modulation of SMCs. 25, 26 The precise molecular mechanisms whereby Runx2 interferes with SRF/Myocd complex formation, however, remain largely unknown.
Olfactomedin 2 (Olfm2) belongs to the family of olfactomedin domain-containing proteins consisting of at least 13 members in mammals. [27] [28] [29] It is well established that Olfm2 is a developmentally regulated gene and involved in early eye development and function. [30] [31] [32] Our previous study indicates that Olfm2 regulates TGF-β-induced SMC differentiation from mesenchymal stem cells. 33 However, it remains unknown whether Olfm2 plays a role in mature SMCs in artery, especially if it is involved in SMC phenotypic modulation, a process of SMC dedifferentiation during pathological vascular remodeling. In an analysis of PDGF-BB-induced phenotypic modulation of primary SMCs, we unexpectedly found that Olfm2 expression was markedly upregulated by PDGF-BB, which prompted us to hypothesize that Olfm2 is involved in PDGF-BB-induced SMC phenotypic modulation. Indeed, our studies showed that knockdown of Olfm2 suppressed PDGF-BB-induced SMC phenotypic modulation. Olfm2 seemed to mediate SRF-Runx2 interaction, which prevented Myocd from binding to SRF, leading to a repressed transcription of SMC marker genes and consequently SMC phenotypic modulation. Consistently, a significant reduction in intimal hyperplasia and an increased level of SMC contractile protein were observed in wire-injured arteries of Olfm2 knockout (Olfm2 −/− ) mice, indicating that Olfm2 is a novel regulator of SMC phenotypic modulation and vascular remodeling.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Olfm2 Was Upregulated During SMC Phenotypic Modulation Both In Vitro and In Vivo
Because Olfm2 is involved in TGF-β-induced SMC differentiation from mesenchymal progenitors in vitro, 33 we examined the expression of Olfm2 in primary rat aortic SMCs treated with PDGF-BB, a SMC phenotype modulator. 1 As shown in Figure 1 , Olfm2 was markedly upregulated 8 hours after PDGF-BB treatment, a time earlier than the reduction of SMC marker genes that occurred 24 hours after the treatment ( Figure 1A through 1D ). Olfm2 expression also correlated with the induction of proliferating cell nuclear antigen (PCNA), a proliferation marker ( Figure 1A and 1E) . Importantly, Olfm2 was expressed at a low level in normal arteries, but its expression was time dependently upregulated in balloon-injured rat carotid arteries ( Figure 1F ) along with the reduction of SMC marker proteins and induction of PCNA in the arteries. Because GTEx database suggests that Olfm2 mRNA is not expressed in several human arteries (http://www.gtexportal.org/home/ gene/OLFM2), we verified the specificity of Olfm2 antibody used in our studies. As shown in Figure IA in the online-only Data Supplement, the Olfm2 antibody detected a single band in SMC isolated from mouse carotid arteries and rat aorta but not in Olfm2 knockout mouse carotid arteries, indicating that the Olfm2 antibody is specific and that Olfm2 was indeed expressed in aorta or carotid artery. Importantly, Olfm2 was mainly expressed in the neointimal and medial SMC in the balloon-injured artery ( Figure IB in the online-only Data Supplement). In fact, Olfm2 was upregulated as early as 1 day after the balloon injury preceding the alteration of MYH11, TAGLN, and PCNA expression ( Figure 1F through 1J), indicating that Olfm2 may be involved in SMC phenotypic modulation in vivo, which eventually leads to vascular remodeling.
Olfm2 Was Required for PDGF-BB-Induced SMC Phenotypic Modulation In Vitro
To determine whether or not Olfm2 plays a role in the modulation of SMC phenotype, we knocked down Olfm2 expression using an adenoviral vector expressing Olfm2 shRNA and examined the expression of SMC markers and PCNA in PDGF-BB-treated rat aortic SMCs. As shown in Figure of PDGF-BB-suppressed SMC markers and inhibited the expression of PDGF-BB-induced PCNA, suggesting that Olfm2 was essential for PDGF-BB-induced SMC phenotypic modulation. On the other hand, the forced expression of Olfm2 suppressed the SMC marker expression and increased PCNA expression ( Figure 2F through 2J), suggesting that Olfm2 was able to mediate a synthetic SMC phenotype. Because phenotypically modulated SMCs exhibit higher growth rates and migratory activity compared with contractile SMCs, 1 we examined whether Olfm2 has effects on SMC proliferation and migration. As shown in Figure 2K through 2M, Olfm2 knockdown significantly inhibited PDGF-BB-induced SMC proliferation ( Figure 2K ) and migration ( Figure 2L through  2M ). These results demonstrate that Olfm2 is a novel factor for SMC phenotypic modulation in vitro.
Olfm2 Was Essential for Injury-Induced SMC Phenotypic Modulation and Vascular Remodeling
To investigate if Olfm2 is functionally important in vascular remodeling in vivo, we knocked down Olfm2 expression in arterial SMCs by incubating the endothelium-denuded rat carotid arteries with adenovirus expressing Olfm2 shRNA for 20 minutes immediately after the balloon injury. Olfm2 expression was dramatically induced in neointimal SMCs. However, its expression was markedly inhibited in Olfm2 shRNA-expressing vessels 14 days after the injury ( Figure  IC in the online-only Data Supplement). Importantly, exogenously introduced adenovirus expressing Olfm2 shRNA significantly reduced neointima formation with a decrease in intima area by 68% and a reduction of intima/media area ratio by 64% ( Figure 3A through 3C) . These results suggest an essential role of Olfm2 in balloon injury-induced vascular remodeling.
Because adenoviral shRNA transduction may only suppress Olfm2 expression in medial SMCs that directly contact with the virus, we performed carotid artery wire injury in Olfm2 knockout (Olfm2 by 83% and 85%, respectively, compared with the wild-type (WT) control ( Figure 3E and 3F) . These data further demonstrate that Olfm2 is critically important for the injury-induced vascular remodeling.
To determine whether Olfm2 regulates SMC phenotypic modulation in vivo after vascular injury, we examined the expression of SMC-specific contractile protein MYH11 in both WT and Olfm2 −/− mouse carotid arteries with and without wire injury. As shown in Figure 3G and 3H, injury attenuated the MYH11 expression in both WT and Olfm2 −/− mouse arteries. However, Olfm2
−/− significantly preserved the MYH11 level in arterial SMCs when compared with the injured WT arteries ( Figure 3G and 3H) . Consistently, Olfm2 −/− led to a marked decrease in the PCNA-positive cells in injured mouse arteries ( Figure IIC and IID in the online-only Data Supplement), suggesting that Olfm2 is important for SMC proliferation in vivo. Together, these data indicate that Olfm2 plays an important role in injury-induced SMC phenotypic modulation in vivo.
Olfm2 Inhibited Myocd Binding to SRF
Myocd is a critical SRF coactivator regulating SMC contractile protein expression. 34, 35 SMC phenotypic modulation is regulated by multiple mechanisms, including suppression of Myocd and SRF expression, disruption of Myocd-SRF interaction, and interference with SRF binding to promoters of SMC-specific markers such as Myh11 and Tagln. 1, 36 Because our previous study indicates that Olfm2 physically interacts with SRF during SMC differentiation, 33 we tested whether
Olfm2 causes a disruption of SRF-Myocd interaction during SMC phenotypic modulation. As shown in Figure 4A and 4B, forced expression of Olfm2 inhibited the physical binding of Myocd to SRF by 54% in cultured SMCs. Olfm2 seemed not to affect SRF or Myocd expression ( Figure 4A ), suggesting that Olfm2 disrupted SRF-Myocd interaction not by altering SRF or Myocd expression. Moreover, there was no change in the binding affinity of SRF to Myh11 and Tagln promoters in Olfm2-expressing SMCs ( Figure 4C through 4E) . These results indicate that the dissociation between SRF and Myocd is a major mechanism underlying Olfm2 function in the SMC phenotypic modulation.
Olfm2 Mediated Runx2 Binding to SRF
It has been reported that Runx2 binds to SRF and competitively inhibits Myocd binding to SRF and thus regulates SMC phenotypic modulation. 25, 26 We therefore tested whether Olfm2 is involved in the Runx2 activity in the SRF-Myocd interaction. Interestingly, PDGF-BB only induced a modest increase in Runx2 expression (1.5-fold) 24 hours after the induction ( Figure 5A and 5B). Similarly, a marginal, but not significant, increase in Runx2 expression was observed in ballooninjured rat carotid arteries ( Figure III in the online-only Data Supplement). These findings suggest that the regulation of Runx2 expression may not be a major mechanism controlling SMC phenotypic modulation both in vitro and in vivo. In contrast, PDGF-BB stimulation resulted in a 7. ( Figure 5C and 5D), suggesting that other factors are involved in enhancing the SRF-Runx2 binding. Olfm2 seemed to be one of these factors. Knockdown of Olfm2 attenuated the PDGF-BBinduced SRF-Runx2 interaction ( Figure 5E and 5F), indicating that Olfm2 was required for SRF-Runx2 interaction during SMC phenotypic modulation. Consistently, forced expression of Olfm2 promoted SRF-Runx2 interaction ( Figure 5G and  5H ). These results demonstrate that Olfm2 regulates SMC phenotypic modulation by facilitating SRF-Runx2 binding. In addition to Runx2, Kruppel-like factor 4 (KLF4) also interacts with SRF to mediate PDGF-BB-induced SMC phenotypic modulation. 10 ,37 Therefore, we tested whether Olfm2 has effects on KLF4. As shown in Figure IVA through IVC in the online-only Data Supplement, KLF4 was expressed at a low level in SMCs, and Olfm2 did not regulate KLF4 expression. Moreover, Olfm2 did not alter KLF4 binding to SRF in KLF4-expressing SMCs ( Figure IVD and IVE in the online-only Data Supplement). Therefore, Olfm2 and KLF4 may regulate SMC phenotypic modulation independently. Together, these results indicate that Olfm2 couples Runx2, but not KLF4, to block SRF-Myocd interaction and thus modulate SMC phenotype.
Runx2 Physically Interacted With Olfm2 and Mediated Its Function in Inhibiting SRF-Myocd Binding
As Olfm2 mediated SRF-Runx2 interaction, we test whether Olfm2 interacts with Runx2. Co-IP assays showed that Olfm2 physically interacted with Runx2 in SMCs ( Figure 6A and  6C) , and PDGF-BB significantly enhanced their interaction ( Figure 6A through 6D) , which was likely because of the increased expression of Olfm2 by PDGF-BB. These results suggest that Olfm2 may mediate Runx2-SRF binding through its binding with both Runx2 and SRF.
Because both Olfm2 and Runx2 can disrupt SRF-Myocd interaction, we sought to determine whether Olfm2-mediated dissociation of Myocd from SRF was dependent on Runx2. As shown in Figure 6E through 6H, knockdown of Runx2 by its specific shRNA restored the Myocd-SRF interaction that was inhibited by Olfm2, indicating that Runx2 played an essential role in mediating the Olfm2 disruption of SRF-Myocd binding during SMC phenotypic modulation.
To verify the effect of Myocd-SRF interaction that is mediated by Olfm2 and Runx2 on SMC marker gene transcription, we tested whether endogenous Olfm2 has effects on Runx2 and Myocd association with the CArG box in endogenous smooth muscle myosin heavy chain promoter in PDGF-BB-treated rat aortic SMCs. ChIP analyses showed that shRNA knockdown of Olfm2 inhibited the Runx2 while promoted the Myocd association with the CArG box ( Figure V in the online-only Data Supplement). These data further support that Olfm2 facilitates Runx2 binding to SRF that directly interacts with CArG box, which competitively inhibits Myocd interaction with SRF.
Discussion
SMC phenotypic modulation contributes to the pathogenesis of a variety of cardiovascular disorders, including restenosis after angioplasty, atherosclerosis, and hypertension. 1 However, the precise molecular mechanisms underlying this process are not fully understood. In this study, we have identified Olfm2 as a novel regulator for SMC phenotypic modulation both in vitro and in vivo. Olfm2 expression is significantly increased both in PDGF-BB-treated SMCs and in injured arteries ( Figure 1 ). Importantly, Olfm2 deficiency restores the suppression of SMC marker proteins induced by PDGF-BB or vascular injury (Figures 2 and 3 ), indicating that Olfm2 promotes SMC phenotypic modulation both in vitro and in vivo. Interestingly, the uninjured carotid arteries in Olfm2 −/− mice exhibit higher expression of SMC-specific marker proteins than those in WT mice (Figure 3 ), suggesting that a low level of Olfm2 is required for preventing an excessive expression of contractile proteins in quiescent SMCs, although Olfm2 is needed for SMC differentiation from the progenitors. The suppressive role of Olfm2 in SMC marker gene expression is further supported by the facts that ectopic expression of Olfm2 inhibits MYH11 and TAGLN expression in cultured SMCs (Figure 2 ). Consistent with these findings, Olfm2 deficiency also suppresses PDGF-BB-induced SMC proliferation and migration in vitro and injury-induced neointima formation/vascular remodeling in vivo (Figures 2 and 3) .
Olfm2 seems to regulate SMC phenotypic modulation by promoting Runx2 binding to SRF. Runx2 has been shown to occupy the Myocd docking site on SRF, and thus competitively inhibiting the association of Myocd with SRF, which subsequently leads to the repression of SMC marker gene transcription. 25 Olfm2 physically interacts with both Runx2 and SRF (Figures 5 and 6 ), which renders Olfm2 capable of carrying Runx2 toward SRF, mediating Runx2/SRF interaction, and consequently disrupting SRF/Myocd association. Indeed, knockdown of Olfm2 blocks PDGF-BB-induced Runx2/SRF interaction ( Figure 5 ). It seems that Runx2 binds to SRF with a relatively low affinity, and Olfm2 serves as a glue to secure Runx2 adhesion to SRF to effectively compete with Myocd for the docking site on SRF. Equally, Runx2 is also essential for mediating Olfm2 function in SMC phenotypic modulation because knockdown of Runx2, without affecting Olfm2 expression, rescues the SRF-Myocd binding impaired by Olfm2 (Figure 6 ). It seems that Olfm2 and Runx2 work coordinately in PDGF-BB-induced SMC phenotypic modulation, that is, Olfm2 provides physical support for Runx2 association with SRF, whereas Runx2 diminishes the availability of docking sites for Myocd and therefore prevents Myocd from binding to SRF.
Facilitating Runx2 binding to SRF and consequently disrupting Myocd-SRF binding seems to be the major mechanism underlying Olfm2 function in SMC phenotypic modulation because Olfm2 neither modifies Myocd and SRF expression nor interferes with SRF/CArG box association (Figure 4) . Because it is known that the dissociation of myocardin from SRF normally results in a reduction in SRF-CArG binding, the absence of this effect by Olfm2 must be because of the binding of Runx2 to the SRF. Indeed, Runx2 has been shown to increase SRF binding to CArG boxes in both Myh11 and Tagln promoters. 25 In addition, although KLF4 plays a critical role in SMC phenotypic modulation, Olfm2 seems to work in a KLF4-independent manner ( Figure Data Supplement). Unlike the function of Olfm2 in disrupting SRF/Myocd interaction, KLF4 has been shown to reduce Myocd expression, SRF binding to CArG box and SRF/ Myocd binding, 10, 38, 39 indicating that Olfm2 and KLF4 regulate SMC phenotypic modulation via distinct mechanisms.
Our previous study revealed that Olfm2 regulated TGF-β-induced SMC differentiation from mesenchymal stem cells. 33 It is paradoxical that Olfm2 plays dual roles in both SMC differentiation and phenotypic modulation. The possible explanation is that the roles of Olfm2 depend on the cellular context. In SMC precursors such as mesenchymal stem cells, the expression of Runx2 is undetectable, and Runx2 is not induced by TGF-β (data not shown). As a result, Olfm2 does not impair the SRF/Myocd interaction. Instead, it promotes the dissociation of SRF from HERP1 (HES [hairy and enhancer of split]-related repressor protein 1), a transcriptional repressor for SMC gene, to enhance SRF-CArG box interaction. These paradoxical results suggest that cellular environments could influence the protein function dramatically. Olfm2 may promote or suppress SMC marker gene expression depending on its cooperation with either HERP1 during normal SMC differentiation or Runx2 in the pathological vascular remodeling process.
Taken together, our present study demonstrates that Olfm2 is a novel regulator for SMC phenotypic modulation both in vitro and in vivo. Therefore, targeting Olfm2 may hinder injury-induced vascular remodeling and thus improve vascular repair.
